— Know what they know.
Not Investment Advice

EVFM OTC

Evofem Biosciences, Inc.
1W: -3.9% 1M: -7.5% 3M: -22.1% YTD: -22.1% 1Y: -44.8% 3Y: -94.7% 5Y: -100.0%
$0.01
+0.00 (+10.81%)
 
Weekly Expected Move ±7.8%
$0 $0 $0 $0 $0
OTC · Healthcare · Biotechnology · Tech Score Sell · Power 40 · $1.1M mcap · 133M float · 0.172% daily turnover · Short 15% of daily vol

Cash Flow Trends

Operating Cash Flow
-$2M +48.7% ▲
Capital Expenditures
$5K +64.3% ▲
5Y CAGR: -70.5%
Free Cash Flow
-$2M +48.8% ▲
Dividends Paid
$117K +0.0% ▲
Buybacks
$0 +0.0% ▲
Net Change in Cash
-$163K -201.2% ▼

Cash Flow Composition

Year-over-Year Growth

View Full Cash Flow Statement
Line ItemFY2021FY2022FY2023FY2024FY2025
— Operating Activities —
Net Income-$205M-$77M$53M-$9M$274K
Depreciation & Amort.$1M$2M$2M$756K$518K
Stock-Based Comp.$9M$3M$1M$847K$166K
Change in Working Capital$11M$6M$5M$867K$583K
Other Non-Cash Items$38M-$5M-$70M$3M-$4M
Operating Cash Flow-$147M-$70M-$9M-$4M-$2M
— Investing Activities —
Capital Expenditures-$3M-$341K-$4K-$14K-$5K
Acquisitions (Net)$250K$0$0-$555K-$57K
Investment Purchases$0$0$0$0$0
Investment Sales$0$0$0$0$0
Other Investing$0$0$0$0$0
Investing Cash Flow-$3M-$341K-$4K-$569K-$62K
— Financing Activities —
Net Debt Issuance$0$6M$4M-$385K$2M
Stock Repurchased$0-$18K$0$0$0
Dividends Paid$0$0$0$0-$117K
Other Financing-$841K$24M$290K$0$105K
Financing Cash Flow$91M$62M$5M$5M$2M
Net Change in Cash-$59M-$9M-$4M$161K-$163K
Cash End of Period$14M$5M$580K$741K$578K
Free Cash Flow-$150M-$71M-$9M-$4M-$2M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms